CrossrefCarte d’information
RNF216 as a Promising Biomarker for Prognosis, Immunotherapy, and Chemotherapy in LIHC: A Comprehensive Pan-Cancer Analysis and Experimental Validation
Journal of Cancer · 2026-01-30 · 17 (3) · 483-506
DOI: 10.7150/jca.125407 ↗Résumé
Aucun résumé disponible.
EUVIMED